

REAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTHRITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP.

J. POQUET-JORNET (1), F. ROGRIGUEZ-LUCENA (2), M.C. RODRIGUEZ-SAMPER (3), M.A. BERNABEU-MARTINEZ (4), A. GARCIA-MONSALVE (5), M.A. CIA-BARRIO (6), M. PRIETO-CASTELLO (7), R. FUSTER-RUIZ DE APODACA (8), A. MOYA-MARTINEZ (5).

(1) HOSPITAL DE DENIA, DENIA, SPAIN. (2) HOSPITAL VEGA BAJA, ORIHUELA, SPAIN. (3) HOSPITAL GENERAL UNIVERSITARIO DE ELDA,, ELDA, SPAIN. (4) HOSPITAL UNIVERSITARIO SAN JUAN, SAN JUAN, SPAIN. (5) HOSPITAL GENERAL UNIVERSITARIO DE ELCHE, ELCHE, SPAIN. (6) HOSPITAL VILA JOIOSA, SPAIN. (7) HOSPITAL VIRGEN DE LOS LIRIOS, ALCOY, SPAIN. (8) HOSPITAL GENERAL UNIVERSITARIO DR. BALMIS, ALICANTE, SPAIN.

Background and Importance

- ✓ Guselkumab is approved for the treatment of psoriasis and psoriatic arthritis.
- ✓ Nonetheless, patients who participate in clinical trials are quite different from those seen in daily clinical practice.

Aim and Objectives

- ✓ Objective: to assess **effectiveness and drug survival** in patients who suffer from **psoriasis and psoriatic arthritis** in real-life settings treated with Guselkumab in **eight hospitals** in Valencian Community (Spain).

Materials and Methods

- ✓ Multicentric retrospective study approved by the Drug Research Ethics Committee (CEIm).
- ✓ Adult patients with psoriasis and psoriatic arthritis
- ✓ Inclusion criteria: patients with previous exposure to one or more biologic drugs and received Guselkumab
- ✓ Period analyzed: April 2019- October 2022 (42 months).

Results



184 patients




52.2% (n = 88)


Mean (± SD) age at initiation of Guselkumab therapy

- ✓ Psoriasis patients: 37,3 ± 17.0
- ✓ Psoriatic arthritis: 47,1 ± 14 (p< 0.05).


Pathology




Previous lines of treatment



First line of treatment




Mean (± SD) PASI score decreased



Results similar observed that pivotal trials VOYAGE 1, VOYAGE 2 and NAVIGATE

Reason for discontinuation (n=21)



Overall cumulative drug survival: 87.0 % at 42 months.

Conclusion and Relevance

This multicenter retrospective study analyzed data from eight hospitals at Valencian Community (Spain), **demonstrating effectiveness and drug survival of Guselkumab in a real-world setting.**

